Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 703.40K | 525.20K | 1.13M | 489.30K | 371.70K |
| Depreciation & Amortization | 1.20K | 1.20K | 1.20K | 1.20K | 1.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 886.80K | 712.10K | 1.88M | 637.40K | 542.60K |
| Operating Income | -886.80K | -712.10K | -1.88M | -637.40K | -542.60K |
| Income Before Tax | -923.30K | -744.90K | -1.91M | -655.90K | -539.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -923.30K | -744.90K | -1.91M | -655.90K | -539.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -923.30K | -744.90K | -1.91M | -655.90K | -539.60K |
| EBIT | -886.80K | -712.10K | -1.88M | -637.40K | -542.60K |
| EBITDA | -885.60K | -710.90K | -1.88M | -636.20K | -541.50K |
| EPS Basic | -2.02 | -3.92 | -2.74 | -0.94 | -1.49 |
| Normalized Basic EPS | -0.82 | -0.67 | -1.71 | -0.59 | -0.49 |
| EPS Diluted | -2.02 | -3.92 | -2.74 | -0.94 | -1.49 |
| Normalized Diluted EPS | -0.82 | -0.67 | -1.71 | -0.59 | -0.49 |
| Average Basic Shares Outstanding | 699.50K | 699.60K | 696.80K | 694.30K | 694.30K |
| Average Diluted Shares Outstanding | 699.50K | 699.60K | 696.80K | 694.30K | 694.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |